Glucagonoma syndrome and necrolytic migratory erythema

International Journal of Dermatology

Volumn 49, Issue 1, 2010, Pages 24-29

  Lobo, Inês ^a   Carvalho, André ^a   Amaral, Cláudia ^a   Machado, Susana ^a   Carvalho, Rui ^a  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ABDOMINAL MASS; AGED; ANEMIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG TREATMENT FAILURE; ECZEMA; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; GLUCAGONOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOPROTEINEMIA; INSULIN TREATMENT; LABORATORY DIAGNOSIS; MALE; NECROLYTIC MIGRATORY ERYTHEMA; PANCREAS RESECTION; PRURITUS; RASH; WEIGHT REDUCTION;

AGED; BIOPSY; ERYTHEMA; GLUCAGON; GLUCAGONOMA; HUMANS; MALE; NECROSIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; SKIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 73149083219     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04220.x     Document Type: Article

References (24)

1. Wermers RA, Fatourechi V, Wynne AG. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine 1996, 75:53-63.
2. Remes-Troche JM, García-de-Acevedo B, Zuñiga-Varga J. Necrolytic migratory erythema: a cutaneous clue to glucagonoma syndrome. J Eur Acad Dermatol Venereol 2004, 18:591-595.
3. Johnson SM, Smoller RB, Lamps LW, Horn TD. Necrolytic migratory erythema as the only presenting sign of a glucagonoma. J Am Acad Dermatol 2003, 49:325-328.
4. Shepherd ME, Raimer SR, Tyring SK, Smith EB. Treatment of necrolytic migratory erythema in glucagonoma syndrome. J Am Acad Dermatol 1991, 25:925-928.
5. Alkemade JA, van Tongeren JH, van Haelst UJ. Delayed diagnosis of glucagonoma syndrome. Clin Exp Dermatol 1999, 24:455-457.
6. Prout TM, Taylor AJ. Case of the season: glucagonoma syndrome. Semin Roentgenol 2005, 40:4-7.
7. Echenique-Elizondo M, Tuneu Valls A, Elorza Orúe JL. Glucagonoma and pseudoglucagonoma syndrome. JOP 2004, 5:179-185.
8. Nightingale KJ, Davies MG, Kingsnorth AN. Glucagonoma syndrome: survival 24 years following diagnosis. Dig Surg 1999, 16:68-71.
9. Vandersteen PR, Scheithauer BW. Glucagonoma syndrome: a clinicopathologic, immunocytochemical and ultrastructural study. J Am Acad Dermatol 1985, 12:1032-1039.
10. Haneke E. Acquired zinc deficiency mimicking glucagonoma dermatitis. Histology and electron microscopy. Z Hautkr 1984, 59:902-908.
11. Hoitsma HF, Cuesta MA, Starink TM. Zinc deficiency syndrome versus glucagonoma syndrome. Arch Chir Neerl 1979, 31:131-140.
12. el Darouti M, Abu el Ela M. Necrolytic acral erythema: a cutaneous marker of viral hepatitis C. Int J Dermatol 1996, 35:252-256.
13. van Beek AP, de Haas ER, van Vloten WA. The glucagonoma syndrome and necrolytic migratory erythema: a clinical review. Eur J Endocrinol 2004, 151:531-537.
14. Adam DN, Cohen PD, Ghazarian D. Necrolytic migratory erythema: case report and clinical review. J Cutan Med Surg 2003, 7:333-338.
15. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001, 321:306-320.
16. Alexander EK, Robinson M, Staniec M. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin Endocrinol 2002, 57:827-831.
17. Mullans EA, Cohen PR. Iatrogenic necrolytic migratory erythema: a case report and review of nonglucagonoma-associated necrolytic migratory erythema. J Am Acad Dermatol 1998, 38:866-873.
18. Tierney EP, Badger J. Etiology and pathogenesis of necrolytic migratory erythema: review of the literature. MedGenMed 2004, 6:4.
19. Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev 1981, 2:347-361.
20. Soga J, Yakuwa Y. Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg 1998, 5:312-319.
21. Wermers RA, Fatourechi V, Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clin Proc 1996, 71:1030-1038.
22. Faiss S, Pape UF, Böhmig M. International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003, 21:2689-2696.
23. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998, 93:1468-1471.
24. Edney JA, Hofmann S, Thompson JS, kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entity. Am J Surg 1990, 160:625-628.